keyword
MENU ▼
Read by QxMD icon Read
search

breast neoadjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/29244990/clinical-and-epidemiological-profile-of-breast-cancer-in-mexico-results-of-the-seguro-popular
#1
Nancy Reynoso-Noverón, Cynthia Villarreal-Garza, Enrique Soto-Perez-de-Celis, Claudia Arce-Salinas, Juan Matus-Santos, María Teresa Ramírez-Ugalde, Alberto Alvarado-Miranda, Paula Cabrera-Galeana, Abelardo Meneses-García, Fernando Lara-Medina, Enrique Bargalló-Rocha, Alejandro Mohar
Purpose One half of the Mexican population lacks comprehensive health care coverage. In 2003, a reform to the General Health Law was approved that led to the creation of the System of Social Protection in Health and made universal health coverage mandatory. The main innovation of this reform was Seguro Popular, which provided coverage for breast cancer. Here we report the outcomes of women with breast cancer treated at a cancer center in Mexico under Seguro Popular. Materials and Methods This was a retrospective cohort study that included all patients with breast cancer treated in the Instituto Nacional de Cancerología in Mexico City between January 2007 and December 2013 with Seguro Popular coverage...
December 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/29242042/neoadjuvant-chemotherapy-in-breast-cancer-more-than-just-downsizing
#2
Marloes G M Derks, Cornelis J H van de Velde
No abstract text is available yet for this article.
December 11, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29242041/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast-cancer-meta-analysis-of-individual-patient-data-from-ten-randomised-trials
#3
(no author information available yet)
BACKGROUND: Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after surgery. We investigated the long-term benefits and risks of NACT and the influence of tumour characteristics on outcome with a collaborative meta-analysis of individual patient data from relevant randomised trials. METHODS: We obtained information about prerandomisation tumour characteristics, clinical tumour response, surgery, recurrence, and mortality for 4756 women in ten randomised trials in early breast cancer that began before 2005 and compared NACT with the same chemotherapy given postoperatively...
December 11, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29238974/a-randomized-phase-iii-trial-of-neoadjuvant-recombinant-human-endostatin-docetaxel-and-epirubicin-as-first-line-therapy-for-patients-with-breast-cancer-cbcrt01
#4
Jianghao Chen, Qing Yao, Meiling Huang, Bo Wang, Juliang Zhang, Ting Wang, Yu Ming, Xiaodong Zhou, Qianxin Jia, Yi Huan, Jing Wang, Ling Wang
To further assess the efficacy and safety of recombinant human endostatin (rh-endostatin), a phase III, multicenter, prospective, randomized, controlled clinical trial was conducted. Patients to be treated with neoadjuvant docetaxel and epirubicin (DE) or DE plus rh-endostatin (DEE) were eligible for this trial. The primary endpoint was clinical/pathological response. Secondary endpoints included adverse events and quality of life (QOL). Finally, 803 patients were enrolled and randomly assigned to receive DE (n = 402) or DEE (n = 401) regimen...
December 14, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29238749/a-feasibility-study-of-neoadjuvant-talazoparib-for-operable-breast-cancer-patients-with-a-germline-brca-mutation-demonstrates-marked-activity
#5
J K Litton, M Scoggins, D L Ramirez, R K Murthy, G J Whitman, K R Hess, B E Adrada, S L Moulder, C H Barcenas, V Valero, J Schwartz Gomez, E A Mittendorf, A Thompson, T Helgason, G B Mills, H Piwnica-Worms, B K Arun
This study was undertaken to determine the feasibility of enrolling breast cancer patients on a single-agent-targeted therapy trial before neoadjuvant chemotherapy. Specifically, we evaluated talazoparib in patients harboring a deleterious BRCA mutation (BRCA+). Patients with a germline BRCA mutation and ≥1 cm, HER2-negative primary tumors were eligible. Study participants underwent a pretreatment biopsy, 2 months of talazoparib, off-study core biopsy, anthracycline, and taxane-based chemotherapy ± carboplatin, followed by surgery...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29234252/targeted-intraoperative-radiotherapy-tumour-bed-boost-during-breast-conserving-surgery-after-neoadjuvant-chemotherapy-a-subgroup-analysis-of-hormone-receptor-positive-her2-negative-breast-cancer
#6
Hans-Christian Kolberg, György Lövey, Leyla Akpolat-Basci, Miltiades Stephanou, Peter Fasching, Michael Untch, Oliver Hoffmann, Max Bulsara, Jayant Vaidya, Cornelia Liedtke
Introduction: In a previous study our group showed a beneficial effect of targeted intraoperative radiotherapy (TARGIT-IORT) as an intraoperative boost on overall survival after neoadjuvant chemotherapy (NACT) compared to an external boost (EBRT). In this study we present the results of a detailed subgroup analysis of the hormone receptor (HR)-positive HER2-negative patients. Methods: In this cohort study involving 46 patients with HR-positive HER2-negative breast cancer after NACT, we compared the outcomes of 21 patients who received an IORT boost to those of 25 patients treated with an EBRT boost...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234251/targeted-intraoperative-radiotherapy-tumour-bed-boost-during-breast-conserving-surgery-after-neoadjuvant-chemotherapy
#7
EDITORIAL
Jayant S Vaidya, Jeffrey S Tobias
No abstract text is available yet for this article.
October 2017: Breast Care
https://www.readbyqxmd.com/read/29233559/tumour-infiltrating-lymphocytes-and-prognosis-in-different-subtypes-of-breast-cancer-a-pooled-analysis-of-3771-patients-treated-with-neoadjuvant-therapy
#8
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto, Wolfgang D Schmitt, Jens-Uwe Blohmer, Thomas Karn, Berit M Pfitzner, Sherko Kümmel, Knut Engels, Andreas Schneeweiss, Arndt Hartmann, Aurelia Noske, Peter A Fasching, Christian Jackisch, Marion van Mackelenbergh, Peter Sinn, Christian Schem, Claus Hanusch, Michael Untch, Sibylle Loibl
BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, but their role in luminal breast cancer and the effect of TILs on prognosis in all subtypes is less clear. Here, we assessed the relevance of TILs for chemotherapy response and prognosis in patients with TNBC, HER2-positive breast cancer, and luminal-HER2-negative breast cancer. METHODS: Patients with primary breast cancer who were treated with neoadjuvant combination chemotherapy were included from six randomised trials done by the German Breast Cancer Group...
December 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29230610/predictive-value-of-vascular-endothelial-growth-factor-receptor-type-2-in-triple-negative-breast-cancer-patients-treated-with-neoadjuvant-chemotherapy
#9
Nataliya Babyshkina, Marina Zavyalova, Natalia Tarabanovskaya, Tatyana Dronova, Nadejda Krakhmal, Elena Slonimskaya, Julia Kzhyshkowska, Evgeny Choynzonov, Nadejda Cherdyntseva
The identification of informative biomarkers that could predict the treatment response is particularly important in the triple-negative (TN) breast cancer, which is characterized by biological diversity. The aim of this study was to investigate the impact of vascular endothelial growth factor receptor (VEGFR2) expression and its gene polymorphisms on pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) in Russian patients with TN breast cancer. We performed a retrospective analysis of 70 women with operable TN breast cancer, who underwent NCT with 5-fluorouracil, adriamycin, and cyclophosphamide (FAC) or cyclophosphamide, adriamycin, and capecitabine (CAX) between 2007 and 2013...
December 11, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/29229152/omission-of-radiotherapy-after-breast-conservation-surgery-in-the-postneoadjuvant-setting
#10
Andrew C Esposito, James Crawford, Elin R Sigurdson, Elizabeth A Handorf, Shelly B Hayes, Marcia Boraas, Richard J Bleicher
BACKGROUND: Breast conservation therapy (BCT) consists of breast conservation surgery (BCS) and radiotherapy (RT). Neoadjuvant chemotherapy (NACT) can downstage tumors, broadening BCS eligibility in patients requiring mastectomy. However, tumor downstaging does not obviate need for RT. This study evaluated factors that predict RT omission after NACT and BCS. METHODS: The National Cancer Database was queried for women with unilateral, clinical stage II-III breast cancer, treated with NACT and BCS between 2008 and 2012...
January 2018: Journal of Surgical Research
https://www.readbyqxmd.com/read/29228315/comparison-of-neoadjuvant-nab-paclitaxel-carboplatin-vs-nab-paclitaxel-gemcitabine-in-triple-negative-breast-cancer-randomized-wsg-adapt-tn-trial-results
#11
Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, Matthias Christgen, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Nikola Bangemann, Christoph Lindner, Sherko Kuemmel, Michael Clemens, Jochem Potenberg, Peter Staib, Andreas Kohls, Raquel von Schumann, Ronald Kates, Ronald Kates, Johannes Schumacher, Rachel Wuerstlein, Hans Heinrich Kreipe, Nadia Harbeck
Background: Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycline-taxane results in higher pCR rates with uncertain survival impact. We evaluated carboplatin vs gemcitabine with a nab-paclitaxel backbone as a short 12-week A-free regimen with a focus on early response. Methods: Patients with TNBC (estrogen receptor/progesterone receptor < 1%, human epidermal growth factor receptor 2-negative, cT1c-cT4c, cN0/+) were randomly assigned to A: nab-paclitaxel 125 mg/m2/gemcitabine 1000 mg/m2 d1,8 three times weekly (q3w); vs B: nab-paclitaxel 125 mg/m2/carboplatin AUC2 day 1,8 q3w...
December 8, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29225623/ki-67-expression-by-immunohistochemistry-and-quantitative-real-time-polymerase-chain-reaction-as-predictor-of-clinical-response-to-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer
#12
Prihantono Prihantono, Mochammad Hatta, Christian Binekada, Daniel Sampepajung, Haryasena Haryasena, Berti Nelwan, Andi Asadul Islam, Andi Nilawati Usman
Background: Chemotherapy has become a standard of treatment in managing breast cancer. To achieve proper treatment for the right patients, the predictive marker is needed. Ki-67 is a biomarker of proliferation for solid tumor. Studies mentioned association of Ki-67 expression with chemotherapy response. The study aims are to evaluate whether Ki-67 expression detected by immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT-PCR) may predict clinical response to neoadjuvant chemotherapy in breast cancer...
2017: Journal of Oncology
https://www.readbyqxmd.com/read/29224273/-ki-67-expression-and-its-effect-on-response-to-neo-adjuvant-chemotherapy-in-invasive-breast-cancer
#13
X X Wei, R Zhang, T J Pu, L B Yang, F Ye, H Bu
Objective: To investigate the response to neoadjuvant chemotherapy (NAC) among different molecular subtypes of breast cancers using molecular classification with Ki-67 (ER+ PR+ HER2+ Ki-67) or without Ki-67 (ER+ PR+ HER2). Methods: One hundred and twenty-seven cases of invasive breast cancer confirmed by core needle biopsy before NAC were collected from January 2007 to December 2009 and diagnosed at West China Hospital, Sichuan University. The cases were classified into different molecular subtypes using molecular classifications with or without Ki-67...
December 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29223797/clinical-impact-of-adjuvant-radiation-therapy-delay-after-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer
#14
Saulo Brito Silva, Allan Andresson Lima Pereira, Gustavo Nader Marta, Kennya Medeiros Lopes de Barros Lima, Thiago Brasileiro de Freitas, Adriana Reis Brandão Matutino, Manoel Carlos Leonardi de Azevedo Souza, Renata Gondim Meira Velame de Azevedo, Pedro Antonio Hermida de Viveiros, Julianne Maria da Silva Lima, José Roberto Filassi, Heloísa de Andrade Carvalho, José Roberto Morales Piato, Max S Mano
BACKGROUND: and Purpose: Post-operative radiation therapy (PORT) is usually indicated for patients with breast cancer (BC) after neoadjuvant chemotherapy (NAC) and surgery. However, the optimal timing to initiation of PORT is currently unknown. MATERIAL AND METHODS: We retrospectively evaluated data from patients with BC who received PORT after NAC and surgery at our institution from 2008 to 2014. Patients were categorized into three groups according to the time between surgery and PORT: <8 weeks, 8-16 weeks and >16 weeks...
December 6, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29223479/long-term-efficacy-analysis-of-the-randomised-phase-ii-tryphaena-cardiac-safety-study-evaluating-pertuzumab-and-trastuzumab-plus-standard-neoadjuvant-anthracycline-containing-and-anthracycline-free-chemotherapy-regimens-in-patients-with-her2-positive-early
#15
Andreas Schneeweiss, Stephen Chia, Tamas Hickish, Vernon Harvey, Alexandru Eniu, Maeve Waldron-Lynch, Jennifer Eng-Wong, Sarah Kirk, Javier Cortés
BACKGROUND: We report long-term efficacy and cardiac safety outcomes in patients with HER2-positive early breast cancer treated with neoadjuvant pertuzumab plus trastuzumab with anthracycline-containing or anthracycline-free chemotherapy. METHODS: Descriptive efficacy analyses were conducted in patients randomised to group A (cycles 1-6: trastuzumab [8 mg/kg loading dose and 6 mg/kg maintenance] plus pertuzumab [840 mg loading dose and 420 mg maintenance], plus 5-fluorouracil, epirubicin and cyclophosphamide [FEC] [cycles 1-3; 500 mg/m2 5-fluorouracil/100 mg/m2 epirubicin/600 mg/m2 cyclophosphamide] then docetaxel [cycles 4-6; 75 mg/m2, escalated to 100 mg/m2 if well tolerated]), B (cycles 1-3: FEC, cycles 4-6: trastuzumab plus pertuzumab plus docetaxel as mentioned previously) or C (cycles 1-6: trastuzumab plus pertuzumab plus docetaxel [75 mg/m2, without dose escalation], and carboplatin [AUC 6]), five years after randomisation of the last patient...
December 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29222623/tumor-infiltrating-lymphocytes-in-breast-cancer-patients-with-progressive-disease-during-neoadjuvant-chemotherapy
#16
Jacques Raphael, S Nofech-Mozes, T Paramsothy, N Li, S Gandhi
A minority of breast cancer (BC) patients progress during neoadjuvant chemotherapy (NCT). The aim of this study was to assess the value of Tumor infiltrating lymphocytes (TILs) in such a high-risk population where valid biomarkers are eagerly needed. A retrospective review identified BC patients who either progressed during NCT or achieved a pathologic complete response (pCR). An experienced BC pathologist semi-quantified stromal TILs in pre-treatment core biopsies using hematoxylin and eosin stained slides...
December 8, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29220097/invasive-mucinous-carcinoma-of-the-breast-and-response-patterns-after-neoadjuvant-chemotherapy-nac
#17
Susan Fineberg, Rosemarie Didonato, Nella Shapiro, Tova Koenigsberg, Timothy D'Alfonso, Shabnam Jaffer
AIMS: Neoadjuvant chemotherapy (NAC) is often used to treat localized invasive breast cancer. Invasive mucinous carcinoma (IMC) is considered to be an indolent form of invasive breast cancer and is rarely treated with NAC. We report the largest series of IMC treated with NAC, and report a characteristic, but not well recognized, pattern of pathologic response. METHODS AND RESULTS: Our series included 7 patients with IMC treated with NAC. Three patients presented with locally advanced disease, three patients had tumors that were Her/2Neu positive, and four patients had tumors with admixed mucinous and micropapillary features...
December 8, 2017: Histopathology
https://www.readbyqxmd.com/read/29214416/breast-conserving-surgery-following-neoadjuvant-therapy-a-systematic-review-on-surgical-outcomes
#18
REVIEW
José H Volders, Vera L Negenborn, Pauline E Spronk, Nicole M A Krekel, Linda J Schoonmade, Sybren Meijer, Isabel T Rubio, M Petrousjka van den Tol
PURPOSE: Neoadjuvant chemotherapy (NACT) is increasingly used in breast cancer treatment. One of the main goals of NACT is to reduce the extent of local surgery of the breast and axilla. The aim of this study was to determine surgical outcomes for patients receiving breast-conserving therapy (BCT) after NACT, including margin status plus secondary surgeries, excision volumes, and cosmetic outcomes. METHODS: A systematic review was performed in accordance with PRISMA principles...
December 6, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29212525/establishing-and-characterizing-patient-derived-xenografts-using-pre-chemotherapy-percutaneous-biopsy-and-post-chemotherapy-surgical-samples-from-a-prospective-neoadjuvant-breast-cancer-study
#19
Jia Yu, Bo Qin, Ann M Moyer, Jason P Sinnwell, Kevin J Thompson, John A Copland, Laura A Marlow, James L Miller, Ping Yin, Bowen Gao, Katherine Minter-Dykhouse, Xiaojia Tang, Sarah A McLaughlin, Alvaro Moreno-Aspitia, Anthony Schweitzer, Yan Lu, Jason Hubbard, Donald W Northfelt, Richard J Gray, Katie Hunt, Amy L Conners, Vera J Suman, Krishna R Kalari, James N Ingle, Zhenkun Lou, Daniel W Visscher, Richard Weinshilboum, Judy C Boughey, Matthew P Goetz, Liewei Wang
BACKGROUND: Patient-derived xenografts (PDXs) are increasingly used in cancer research as a tool to inform cancer biology and drug response. Most available breast cancer PDXs have been generated in the metastatic setting. However, in the setting of operable breast cancer, PDX models both sensitive and resistant to chemotherapy are needed for drug development and prospective data are lacking regarding the clinical and molecular characteristics associated with PDX take rate in this setting...
December 6, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29211674/mechanisms-of-resistance-to-neoadjuvant-chemotherapy-in-breast-cancer
#20
Angela DeMichele, Douglas Yee, Laura Esserman
New England Journal of Medicine, Volume 377, Issue 23, Page 2287-2289, December 2017.
December 7, 2017: New England Journal of Medicine
keyword
keyword
55508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"